2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
71
Carcinoma, Hepatocellular
26
Prostatic Neoplasms
22
Neoplasm Metastasis
19
Neoplasms
18
Carcinoma, Non-Small-Cell Lung
16
Kidney Neoplasms
14
Osteosarcoma
9
Neuroendocrine Tumors
9
Colorectal Neoplasms
9
Carcinoma, Transitional Cell
9
Carcinoma, Medullary
9
Sarcoma
8
Urinary Bladder Neoplasms
7
Sarcoma, Ewing
7
Melanoma
7
Breast Neoplasms
7
Brain Neoplasms
7
Thyroid Neoplasms
6
Ovarian Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Recurrence
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Carcinoma
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled